Patent Power: Roche Concedes Case Over Amgen's EPO
Roche will not launch its anemia drug Mircera in the U.S. until Amgen's latest patent expires in 2015 unless it obtains a license.
Roche will not launch its anemia drug Mircera in the U.S. until Amgen's latest patent expires in 2015 unless it obtains a license.